C.Albicans PLB1

C.Albicans PLB1

  • Name
  • Description
  • Cat#
  • Pricings
  • Quantity
  • C.Albicans PLB1

  • Candida Albicans Phospholipase B1 Recombinant
  • PRO-2809
  • Shipped with Ice Packs

Catalogue number



Recombinant Candida Albicans Phospholipase B1 (24-526 a.a) produced in E. coli having a Mw of 52kDa. C.Albicans PLB1 is fused to a 6xHis tag at its C terminal is and purified by proprietary chromatographic technique.


Escherichia Coli.

Physical Appearance

Sterile Filtered colorless solution.


Protein is >90% pure as determined by 10% PAGE (coomassie staining).      


Phosphate buffer and 25mM K2CO3.


Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Safety Data Sheet


ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.


Candida albicans, a commensal fungus in humans, can turn pathogenic under specific conditions, causing a range of infections from superficial mucosal to life-threatening systemic infections. Among the arsenal of virulence factors employed by C. albicans, phospholipases play a crucial role in disrupting host cell membranes. Candida Albicans Phospholipase B1 (PLB1), in its recombinant form, serves as a key tool for investigating the molecular intricacies of fungal pathogenesis and exploring potential avenues for therapeutic intervention. This research embarks on a journey to unravel the multifaceted roles of Recombinant Candida Albicans Phospholipase B1, shedding light on its structural attributes, enzymatic activities, and implications in host-pathogen interactions. By delving into the properties of PLB1, scientists aim to deepen our understanding of C. albicans virulence and pave the way for innovative strategies in antifungal drug development.


Structural Insights into Recombinant Candida Albicans Phospholipase B1:

PLB1, a member of the phospholipase enzyme family, exhibits a complex structural arrangement that facilitates its interaction with host cell membranes. In its recombinant form, PLB1 provides a controlled system for exploring the three-dimensional intricacies of its catalytic domains and lipid-binding regions. Understanding its structure is fundamental for deciphering how PLB1 disrupts host cell membranes and contributes to the virulence of C. albicans.


Enzymatic Activities and Lipid Interactions:

The enzymatic activities of PLB1 are pivotal for its role in fungal pathogenesis. This includes hydrolyzing phospholipids in host cell membranes, leading to membrane destabilization. Recombinant Candida Albicans Phospholipase B1 studies focus on unraveling its substrate specificity, kinetics, and the intricacies of its interactions with different lipid moieties. Insights into these enzymatic activities provide a basis for designing inhibitors that can potentially curb C. albicans virulence.


Implications in Host-Pathogen Interactions:

PLB1's role in host-pathogen interactions extends beyond its enzymatic activities. It contributes to the evasion of host immune responses and facilitates the establishment of fungal infections. Recombinant PLB1 studies illuminate how this virulence factor modulates immune signaling, interferes with host cell functions, and potentially facilitates the dissemination of C. albicans within the host.


Potential as a Therapeutic Target:

Understanding the role of PLB1 in fungal pathogenesis opens avenues for developing novel antifungal strategies. Inhibiting PLB1 activity could potentially render C. albicans less virulent and susceptible to host immune defenses. Recombinant Candida Albicans Phospholipase B1 studies play a critical role in identifying and characterizing potential inhibitors that could form the basis for antifungal drug development.


Challenges and Future Directions:

While the potential of Recombinant Candida Albicans Phospholipase B1 in antifungal research is promising, challenges persist. Fine-tuning its applications, deciphering its role in different infection scenarios, and optimizing strategies for therapeutic use are critical considerations for translational success. Additionally, understanding the interplay between PLB1 and other virulence factors in C. albicans pathogenesis remains an active area of investigation.


Recombinant Candida Albicans Phospholipase B1 emerges as a key player in the intricate dance between the fungus and its human host. Its structural insights, enzymatic activities, and implications in host-pathogen interactions position it as a central focus in the exploration of C. albicans virulence. As researchers continue to unravel the molecular intricacies of PLB1, they not only deepen our understanding of fungal pathogenesis but also pave the way for transformative advancements in antifungal drug development, shaping the future of precision medicine in the realm of fungal infections.


Back to Top